Editing Dermatitis (section)

==== Others ====
In September 2021, [[ruxolitinib|ruxolitinib cream]] (Opzelura) was approved by the U.S. [[Food and Drug Administration]] (FDA) for the topical treatment of mild to moderate atopic dermatitis.<ref name="Incyte PR 20210921">{{cite web | title=Incyte Announces U.S. FDA Approval of Opzelura (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD) | publisher=Incyte | via=Business Wire | date=21 September 2021 | url=https://www.businesswire.com/news/home/20210921006072/en/ | access-date=21 September 2021}}</ref> It is a topical [[Janus kinase inhibitor]].<ref name="Incyte PR 20210921" />